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Background: A recent observational study among HIV-1 serodiscordant couples (uninfected women living with an infected partner)
raised concerns about the safety of injectable contraceptives, especially depot medroxyprogesterone acetate (DMPA). The purpose of this
paper is to assess the implications of potentially elevated risk of Human Immunodeficiency Virus (HIV) acquisition with the use of
hormonal contraceptives for individual users and public policies.
Study Design: Two indicators expressing costs (additional unwanted births and additional maternal deaths) in terms of the same unit of
benefit (per 100 HIV infections averted) are estimated by using data on competing risks of unwanted birth and HIV acquisition associated
with the use of various contraceptive methods. Elevated HIV acquisition risks associated with hormonal contraception observed in the
observational studies of family planning users, sex workers and HIV-1 serodiscordant couples are used. Other relevant data for Kenya,
South Africa and Zimbabwe are used to illustrate the potential effect of withdrawal of DMPA at the population level.
Results: Both the risks of unwanted birth and HIV acquisition with sterilization, intrauterine devices (IUDs) and implants at the individual
level are lower than those with DMPA. A shift from DMPA to an oral contraceptive (OC) or male condom by an individual could result in
about 600 and a shift to no method in about 5400 additional unwanted births per 100 HIV infections averted. At the population level, the
withdrawal of DMPA from Kenya, for example, could result in 7600 annual additional unwanted births and 40 annual additional maternal
deaths per 100 HIV infections averted.
Conclusion: Individual DMPA users may be advised to shift to sterilization, IUD or implant depending upon their reproductive needs and
circumstances, but not to no method, OC or even condom alone. At the macro level, the decision to withdraw DMPA from family planning
programs in sub-Saharan Africa is not warranted.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Keywords: Hormonal contraception; DMPA; HIV acquisition; Policy implications1. Introduction
A recent prospective observational study [1] among
1341 HIV-1 serodiscordant couples (uninfected women
living with an infected partner) indicated that women using
injectable contraception might be exposed to twice the risk
of acquiring Human Immunodeficiency Virus (HIV) from
their infected partners than those who used nonhormonal
contraception. This study has raised concerns about the
safety of injectable contraception, especially depot medrox-
yprogesterone acetate (DMPA). Some governments may
even be contemplating to withdraw the DMPA injectable
from their family planning programs. Is such an actionE-mail address: ajain@popcouncil.org.
0010-7824 © 2012 Elsevier Inc.
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Open access under CC BY-NC-ND license.warranted? Should women using DMPA be advised to shift
to other methods? If so, which one? This paper addresses
these issues by using information available about the
competing risks of unwanted birth and HIV acquisition.
The strengths and weaknesses of previous observational
studies on HIV acquisition risk associated with hormonal
contraception have been reviewed by many researchers
[2–5]. The elevated HIV acquisition risk with hormonal
contraception estimated in these studies may be an artifact
of some of the methodological issues and behavioral
factors, and to some extent may also reflect the biological
effect of hormonal contraception. The proposed random-
ized trial(s) [4] may address some of the methodological
issues involved in prior studies and may refine the
magnitude of the risk involved. However, these random-
ized trials are unlikely to completely eliminate the effect
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waiting for the results of these trials, public discourse
need to shift now to address the implications of the
observational studies for the individual users and for
public policies. This paper is an attempt in this direction.
It assesses the implications of the estimated HIV
acquisition risk for individual DMPA users and public
policies by assuming as if the use of hormonal
contraception would elevate the risk of HIV acquisition.
This analysis is guided by the principle that individuals
would be interested in reducing their risk of having an
unwanted birth as well as their risk of acquiring HIV.
Similarly, the policy makers in a country would be interested
in reducing the spread of HIV as well as reducing fertility
and associated maternal mortality. Such an outcome may not
be possible with DMPA if the elevated HIV risk with its use
turns out to be real. The individuals may be faced with an
unacceptable choice: whether to reduce their risk of having
an unwanted birth but face an elevated risk of HIV
acquisition by continuing with the DMPA or to face a
higher risk of unwanted birth in order to reduce the risk of
HIV acquisition by shifting away from the DMPA.2. Methodology
2.1. Individual DMPA user
A shift from DMPA by an individual to another
contraceptive method may involve some cost in terms of a
higher risk of an unwanted birth and some benefit in terms of
a lower risk of HIV acquisition, which could make the choice
difficult. In order to guide the decision-making process by
individual DMPA users, an index — additional unwanted
births per 100 HIV infections averted — is proposed. This
index can be used to compare various alternatives because itTable 1
Annual probabilities of pregnancy, birth and HIV acquisition by contraceptive me
Contraceptive
method
Annual probability
of pregnancy [6]
Annual probability
of birth
Female sterilization 0.0050 0.00350
Male sterilization 0.0015 0.00105
Levonorgestrel IUD 0.0020 0.00140
Copper IUD 0.0080 0.00560
Net-En 0.0300 0.02100
DMPA 0.0300 0.02100
OC 0.0800 0.05600
Male condom 0.1500 0.10500
Female condom 0.2100 0.14700
No use 0.8500 0.59500
Seventy percent of pregnancies are assumed to result in a birth.
Sterilization and IUDs are assumed to have the same risk of HIV acquisition as use
in preventing HIV infection.
These annual probabilities are multiplied by 100,000 to estimate the number of b
method or no method for 1 year.
References are shown in “[].”measures the magnitude of cost in terms of the same unit of
benefit expected.
This index is estimated by using method-specific risks of
birth and method-specific risks of HIV acquisition. The
method-specific risks of birth are estimated by assuming that
30% of the method-specific pregnancies [6] associated with
1 year of use would be terminated by spontaneous or induced
abortions (Table 1). The number of additional unwanted
births annually expected by shifting from DMPA to another
method is estimated by subtracting the number of expected
births with 1 year of DMPA use from the number of expected
births with 1 year use of another method or no method.
Three scenarios for the elevated HIV acquisition risks
associated with oral contraceptive (OC) and injectable
(DMPA, Net-En) are created. These are based on the annual
incidence rate among users of nonhormonal methods and
adjusted hazard ratios for OC and injectable among family
planning users [7,8], sex workers [9] and uninfected women
living with an infected partner [1]. The annual incidence
rates for OC and DMPA and Net-En users are estimated by
multiplying these adjusted hazard ratios with the respective
annual incidence rates among users of nonhormonal
methods. The use of male and female condom is assumed
to be 85% effective in preventing HIV infections. Other
contraceptive methods [sterilization and intrauterine device
(IUD)] are assumed to have the same HIV acquisition risk as
users of nonhormonal methods (Table 1).
The number of HIV infections averted annually by
shifting from DMPA to another method is estimated by
subtracting the number of new HIV infections expected with
1 year of DMPA use from the number of new HIV infections
expected with 1 year use of another method or no method.
The numbers of unwanted births and new HIV infections
expected among 100,000 women using a particular method
or no method for 1 year are estimated by multiplyingthod
Annual probability of HIV infection
Family planning
users [7,8]
Sex workers [9] Discordant
couples [1]
0.02550 0.06500 0.03780
0.02550 0.06500 0.03780
0.02550 0.06500 0.03780
0.02550 0.06500 0.03780
0.03621 0.11245 0.08278
0.03621 0.11245 0.08278
0.03035 0.09490 0.06161
0.02168 0.05525 0.03213
0.02168 0.05525 0.03213
0.02550 0.06500 0.03780
rs of nonhormonal contraceptives; condoms are assumed to be 85% effective
irths and HIV infections expected among 100,000 women using a specific
Table 2
Contraceptive prevalence, HIV incidence and HIV prevalence rates, and
number of women in 15–49 years of age
Parameters South Africa Kenya Zimbabwe
Current method mix [10,11]
OC 9.0 4.7 26.9
IUD 0.6 1.0 0.2
Injectablea 26.7 14.8 7.2
Male condom 6.0 2.6 2.0
Female condom 0.2 0.0 0.8
Female sterilization 7.3 3.2 1.5
Male sterilization 0.3 0.0 0.0
Implant 0.0 1.3 0.0
No method use 49.8 72.0 61.0
Total 99.9 99.6 99.6
HIV incidence rate [12] 1.490 0.530 0.840
Male 1.146 0.408 0.646
Female 1.834 0.652 1.034
HIV prevalence rate [12] 17.800 6.300 14.300
Male 13.692 4.846 11.000
Female 21.908 7.754 17.600
Women (million) [13] 25.590 20.432 6.526
% Women 15–49 [13] 53.200 48.000 49.700
Women 15–49 (million) 13.614 9.807 3.243
Uninfected women (million) 10.631 9.047 2.673
Births (million) [13] 1.069 1.574 3.900
Total fertility rate [13] 2.42 4.54 3.12
Maternal mortality ratio [14] 410 530 790
References are shown in “[].”
a Includes 15.8% users of DMPA and 10.9% users of Net-En in
South Africa.
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acquisition shown in Table 1.
2.2. Policy options about DMPA
The effect of DMPA withdrawal is likely to be specific to
the country context and will depend upon such factors as
HIV prevalence and incidence rates among women 15–49
years of age, magnitude of HIV acquisition risk attributable
to hormonal contraception, use of injectable, availability of
other methods and what would injectable users do if DMPA
is withdrawn. For comparison purposes, the current method
mix among women 15–49 years of age in a country is taken
as the baseline. The withdrawal of DMPA is also likely to
affect the use of other brands of injectable. It is quite likely
that some injectable users would stop using contraception
altogether and some would shift to other available methods.
To reflect this situation, it is assumed that injection users
would shift to other available methods and no method in
proportion to the current method mix in a country.
This shift would imply some cost— additional unwanted
births and additional maternal deaths — as well as some
benefit — fewer new HIV infections. The effect of DMPA
withdrawal is assessed by using two indicators of costs-to-
benefit ratios — additional unwanted births and additional
maternal deaths per 100 HIV infections averted.
These indicators measure the magnitude of the cost in terms
of the same unit of benefit derived; and thus, various
alternatives can be compared. Their utility is illustrated for
three countries in sub-SaharanAfrica: Kenya, South Africa and
Zimbabwe. The method-specific birth probabilities and HIV
acquisition risks used in the individual-level analysis above are
adjusted to reflect the context in each of these countries.
The method-specific birth probabilities are adjusted so
that the number of births associated with the current method
mix and the estimated number of women 15–49 years of age
equal the projected number of births in that country.
Similarly, the method-specific HIV incidence rates for
family planning users, sex workers and discordant couples
are adjusted so that the overall incidence rate associated with
the current method mix equals the incidence rate for women
15–49 years of age in a country. The HIV incidence and
prevalence rates for women 15–49 years of age are estimated
from these rates for both sexes of the same age and by
assuming that these rates for women are 60% higher than
those for men (see Table 2 for relevant data for Kenya,
South Africa and Zimbabwe used in the present analysis).
The expected number of births, maternal deaths and new
HIV infections are then estimated by using the current
method mix and the scenario for injection users described
above. The number of additional unwanted births is
estimated by subtracting the number of births associated
with the assumed scenario from the number of births
associated with the current method mix. Similarly, the
number of additional maternal deaths and the number of HIV
infections averted are estimated.The effect of country context is assessed by comparing
costs-to-benefit ratios among three countries; the effect of
the magnitude of elevated HIV acquisition risks with
hormonal contraception is assessed by comparing costs-to-
benefit ratios among family planning users with those among
sex workers and discordant couples. The costs-to-befit ratios
are also estimated by varying the percent of injectable users
who stop using contraception to demonstrate the effect of
different assumptions about the behavior of injectable users.2.3. Ethical consideration
No ethical approval for this study is required because it is
based on data from published sources (Tables 1 and 2).3. Results
3.1. Implications for individual DMPA user
It is assumed that individuals would be interested in
minimizing both the risk of an unwanted birth and the risk of
HIV acquisition. From this perspective, sterilization and
nonhormonal IUDs are better than DMPA because both the
risks of pregnancy and HIV acquisition with these methods
are lower than the corresponding risks with DMPA (Table 1).
It is not known whether hormonal IUDs and implants would
0500
000
500
000
Family planning 
users
Sex workers    Discordant couples
No method
Female condom
Male condom
OC
ig. 1. Additional unwanted births per 100 HIV infections averted, at the
dividual level, associated with shift from DMPA to a specified method.
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implants would also be superior to DMPA.
However, the choice between DMPA and OC or condom
or no method is not clear because the risk of unwanted birth
associated with these alternatives is higher than that with
DMPA, but the risk of HIV acquisition with these
alternatives is lower than that with DMPA (Table 1). This
means that a shift from DMPA to OC or to condom or to no
method would involve some cost — additional unwanted
births — and some benefit — prevention of new HIV
infections or HIV infections averted.
As shown in Table 1, the use of DMPA is more effective
than the use of condom, OC or no method in terms of
unwanted births: about 59,500 out of 100,000 women are
expected to give birth to a child if they do not use any
contraceptive method for 1 year; this number reduces to
14,700 with 1-year use of female condom and 10,500 with 1-
year use of male condom, to 5600 with 1-year use of OC and
to 2100 with 1-year use of DMPA (obtained by multiplying
annual probabilities in Table 1 by 100,000). A shift from
DMPA to these alternatives would therefore result in
additional unwanted births ranging from 3500 to 57,400
annually (panel 1, Table 3) [6]. The use of condom is most
effective in terms of preventing new HIV infections. For
example, about 2168 out of 100,000 family planning users
would acquire HIV if they used condom for 1 year in
comparison to 2550 if they did not use any method, 3035 if
they used OC and 3621 if they used DMPA [1,7–9]
(obtained by multiplying annual probabilities in Table 1 by
100,000). The corresponding numbers of new HIV in-
fections for discordant couples would be 3213, 3780, 6161
and 8278, respectively. Consequently, a shift from DMPA to
any one of these alternatives would avert new HIV infections
ranging from 587 to 1454 annually among family planning
users, from 1775 to 5720 annually among sex workers and
from 2117 to 5065 annually among discordant couples per
year (panel 2, Table 3).
The estimated number of annual additional unwanted
births per 100 HIV infections per year averted among familyTable 3
Additional unwanted births per 100 HIV infections averted associated with
shift from DMPA to other methods at the individual level
Indicators Injectable users shift to:
No
method
Female
condom
Male
condom
OC
Additional unwanted births
per 100,000 women
57,400 12,600 8400 3500
HIV infections averted per 100,000 women
Family planning users 1071 1454 1454 587
Sex workers 4745 5720 5720 1775
Discordant couples 4498 5065 5065 2117
Additional unwanted births per 100 HIV infections averted
Family planning users 5359 867 578 597
Sex workers 1210 220 147 166
Discordant couples 1276 249 166 1651
3
4
6
F
inplanning users would range from 597 with a shift to OC,
578 with a shift to male condom, 867 with a shift to female
condom and 5359 with a shift to no method (panel 3,
Table 3; Fig. 1). While the tip-off point would differ from
individual to individual, these comparisons suggest that
continuation with DMPA appears to be a better option than
shifting to either no method or OC or even condom. This
appears to be valid even for high-risk groups of sex workers
and HIV-1 serodiscordant couples (uninfected women living
with an infected partner). Recommending DMPA users to
shift to condom alone would be less effective than
recommending them to use condom in combination with
DMPA or any other contraceptive method, especially if
they can persuade their partners to use condom to reduce
their risk of HIV acquisition.
3.2. Implications for public policy
The question is whether or not to withdraw DMPA from
family planning programs. This policy issue is addressed
within the context of three countries— Kenya, South Africa
and Zimbabwe — with different levels of fertility, maternal
mortality, use of DMPA and other injectables, and HIV
prevalence and incidence rates (Table 2). For example, South
Africa has the lowest fertility and maternal mortality, but the
highest HIV prevalence rate and use of injectable contra-
ception. Kenya, on the other hand, has high fertility but low
HIV prevalence rate, and Zimbabwe has the highest maternal
mortality and the lowest use of injectable contraception. OC
use is also highest in Zimbabwe. The percentage of women
not using any method varies from 50% in South Africa to
72% in Kenya.
With the current method mix and adjusted probabilities of
an unwanted birth, there were about 1.574 million annual
births and 8342 annual maternal deaths in Kenya (column 1,
panel 1, Table 4). These numbers would increase to 1.834
million annual births and 9722 maternal annual deaths if
users of injectable contraception in Kenya shift to other
methods (column 1, panel 2, Table 4). Under this scenario,
the additional number of annual unwanted births would
range between 28,729 in Zimbabwe and 363,335 in South
Table 4
Population-level comparison of costs-to-benefit ratios associated with
withdrawal of injectable contraception fromKenya, South Africa and Zimbabwe
Parameters and
assumptions
Kenya South Africa Zimbabwe
Current method mix
Annual births 1,574,000 1,069,000 390,000
Gross fertility rate 160 79 120
Maternal mortality ratio 530 410 790
Annual maternal deaths 8342 4383 3081
HIV incidence rate 0.652 1.834 1.034
Annual new
HIV infections
59,014 194,963 27,630
Injectable users shift to other methods including no method
Annual births 1,834,280 1,432,335 418,729
Gross fertility rate 187 105 129
Maternal deaths 9722 5873 3308
Additional annual
unwanted births
260,280 363,335 28,729
Additional annual
maternal deaths
1379 1490 227
Family planning users
HIV incidence rate 0.614 1.654 1.008
New HIV infections 55,573 175,856 26,937
HIV infections averted 3440 19,108 693
Additional unwanted
births per 100 HIV
infections averted
7566 1902 4146
Additional maternal
deaths per 100 HIV
infections averted
40 8 33
Sex workers
HIV incidence rate 0.591 1.559 0.995
New HIV infections 53,455 165,770 26,599
HIV infections averted 5558 29,194 1031
Additional unwanted
births per 100 HIV
infections averted
4683 1245 2786
Additional maternal
deaths per 100 HIV
infections averted
25 5 22
Discordant couples
HIV incidence rate 0.558 1.429 0.973
New HIV infections 50,522 151,969 26,009
HIV infections averted 8491 42,995 1621
Additional unwanted
births per 100 HIV
infections averted
3065 845 1772
Additional maternal
deaths per 100 HIV
infections averted
16 3 14
0
000
000
000
000
Kenya           Zimbabwe        South Africa
Family planning users
Sex workers
Discordant couples
ig. 2. Additional unwanted births per 100 HIV infections averted at the
opulation level.
0
0
0
0
0
0
Kenya Zimbabwe South Africa
Family planning users
Sex workers
Discordant couples
ig. 3. Additional maternal deaths per 100 HIV infections averted at the
opulation level.
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range between 227 in Zimbabwe and 1490 in South Africa
(panel 2, Table 4).
Withdrawal of DMPA could decrease the overall annual
HIV incidence rate among family planning users marginally:
from 1.83% to 1.65% annually in South Africa and from
0.65% to 0.61% annually in Kenya (panels 1 and 3, Table 4).
The number of new HIV infections among women 15–49
years of age under the current method mix in South Africa
is estimated to be 194,963 per year (column 2, panel 1,2
4
6
8
F
pTable 4). This number is likely to drop to about 175,876
for family planning users (column 2, panel 3, Table 4). This
means that withdrawal of DMPA could avert from 693
new HIV infections annually in Zimbabwe to 19,108 in
South Africa annually. Additional annual unwanted births
per 100 HIV infections averted among family planning users
would range from 1902 in South Africa to 7566 in Kenya
annually (panel 3, Table 4; Fig. 2). Similarly, additional
annual maternal deaths per 100 HIV infections averted
among family planning users would range from 8 in South
Africa to 40 in Kenya annually (panel 3, Table 4; Fig. 3).
These costs-to-benefit ratios for sex workers (panel 4,
Table 4) and discordant couples (panel 5, Table 4) were
slightly lower than those for family planning users (panel 3,
Table 4). While HIV acquisition risks observed for high-risk
group of women cannot be generalized to the low-risk group
of family planning users, these costs-to-benefits ratios for
all three groups in all three countries indicate that the
decision to withdraw DMPA from the family planning
program in these countries may not be warranted.
3.3. Sensitivity analysis
The above analysis was repeated for different percentage
of injectable contraceptive users who would stop using1
2
3
4
5
F
p
Table 5
Additional unwanted births and additional maternal deaths per 100 HIV infections averted among family planning users by assumptions about injectable
contraceptive users: % who would stop using a contraceptive method and % who would shift to other available methods once DMPA is withdrawn from a country
Assumptions about injectable contraceptive users Additional unwanted births per 100 HIV
infections averted
Additional maternal deaths per 100 HIV
infections averted
% stop using a method % shift to another method Kenya South Africa Zimbabwe Kenya South Africa Zimbabwe
100 0 8868 2672 5407 47 11 43
75 25 6898 2080 4548 37 9 36
50 50 4832 1464 3494 26 6 28
25 75 2661 821 2206 14 3 17
0 100 379 152 550 2 1 4
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costs-to-benefit ratios in all three countries and for all three
levels of HIV acquisition risks (family planning users, sex
workers and discordant couples) increased with an increase
in the proportion of injectable contraceptive users who stop
using contraception altogether. For example, among family
panning users in Kenya, additional annual unwanted births
per 100 HIV infections averted increased from 2661 to 8868
annually and additional annual maternal deaths increased
from 14 to 47 annually as the percentage of injectable users
who stop using contraception increased from 25% to 100%
(Table 5).
The analysis for South Africa was also repeated by
assuming that the elevated HIV acquisition risk associated
with Net-En is the same as for users of nonhormonal
contraception and that withdrawal of DMPA does not
reduce the use of Net-En. These assumptions resulted in
lower costs in terms of additional unwanted births and
additional maternal deaths as well as lower benefit in terms
of HIV infections averted. The costs-to-benefit ratios for
family planning users in South Africa, however, were still
favorable (1583 additional annual unwanted births and 6
additional annual maternal deaths per 100 HIV infections
annually averted).4. Discussion
While the elevated HIV acquisition risk with hormonal
contraception estimated in previous studies may be an
artifact of methodological and behavioral factors involved,
the present analysis identified options for individual DMPA
users and for public policies by assuming as if they were
caused by the use of hormonal contraception. The present
analysis estimated costs- (additional unwanted births and
additional maternal deaths) to-benefit (HIV infections
averted) ratios. While the acceptable cost-to-benefit ratio
would depend upon the individual making the decision,
these ratios can guide the decisions of an individual user, a
health care provider and a program manager in a country.
The decision-making concerning whether to use a
contraceptive method and which method to use is a complex
process. Individuals consider many factors including theirpersonal reproductive needs (whether to have the next child
now, later or never), characteristics of a method, personal
preferences and experiences, and availability and quality of
contraceptive services. However, to make this choice
manageable, we have considered two dimensions — the
risk of an unwanted birth and the risk of HIV acquisition—
associated with 1-year use of various contraceptive methods.
Furthermore, no matter how small the risk of an undesirable
event — unwanted birth or HIV acquisition — with a
contraceptive method, the outcome at the individual level is
1 or 0, i.e., either the individual DMPA user has the event or
she does not. But in terms of selecting an option, one still has
to consider the average risk of an event.
It is assumed that the individual user is interested in
reducing both the risk of an unwanted birth and the risk of
acquiring HIV. From this perspective, for the individual user,
methods like sterilization, IUD and implant may be superior
to the DMPA, but the DMPA appears to be better than no
method, OC or even condom alone. The basic conclusion
remains valid whether we use elevated HIV acquisition risks
observed for family planning users, sex workers or those
living with an infected partner. The application of the
observed elevated HIV risks with hormonal contraception to
data from Kenya, South Africa and Zimbabwe suggests that
the decision to withdraw DMPA from family planning
programs in these countries is not warranted because the cost
of such a decision for family planning users would be high:
100 HIV infections averted annually would be equivalent to
about 1902 additional unwanted births and 8 additional
maternal deaths in South Africa, but 7566 additional
unwanted births and 40 additional maternal deaths in
Kenya. The magnitude of these costs-to-benefit ratios,
however, would depend upon the levels of fertility, maternal
mortality and HIV prevalence; the magnitude of HIV
acquisition risk attributable to injectable use, the percentage
of women using injectable contraception and the percentage
of injectable users who would stop using a method once
DMPA is withdrawn from a country. For example, these
costs-to-benefit ratios for South Africa are low because of the
relatively low fertility and low maternal mortality.
The present analysis has certain limitations. First, it did
not incorporate female-to-male transmission. However, the
conclusion is unlikely to change because the risks of female-
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lower than those of male-to-female HIV transmission [1].
Moreover, those men who are interested in reducing their
risk of HIV acquisition ought to be modifying their sexual
behavior and using condom effectively since they have the
choice of partners in sexual relations and power to
implement their choice.
Second, this analysis did not include the potential
elevated HIV risk due to pregnancy itself. However, the
inclusion of this pregnancy-associated elevated risk of HIV
acquisition would reduce the potential benefit in terms of
HIV infections averted and therefore would further raise the
costs-to-benefit ratios.
Third, the present analysis did not incorporate the effects
of other factors such as unsafe abortions, neonatal
mortality, Acquired Immune Deficiencies Syndrome
(AIDs) mortality, Antiretroviral (ARV), various morbidities
(maternal, neonatal, HIV and AIDs) and second-order
effects of unwanted birth, maternal death and HIV infection
on children, family and the society at large. It would be
difficult to assess the implications of these factors on the
results of this analysis because of the unavailability of
comparative data to quantify these effects. However, some
general speculative comments can be made. For example,
the incorporation of neonatal mortality associated with
maternal deaths would increase the cost and therefore the
costs-to-benefit ratios. Similarly, the incorporation of
maternal and neonatal morbidity would raise the costs-to-
benefit ratios.
The present analysis assumed that 30% of pregnancies
would be terminated by spontaneous and induced
abortions. A higher percentage of induced abortions
among unwanted pregnancies would result in lower
number of unwanted births and lower number of
associated maternal deaths. However, lack of availability
for safe abortion services in a country would result in a
higher number of maternal deaths associated with unsafe
abortions. Most likely, the overall effect would be to
lower the number of unwanted births per 100 HIV
infections but to increase the number of maternal deaths
per 100 HIV infections.
The present analysis measured benefit in terms of HIV
infections averted because it would avert subsequent HIV-
and AIDs-related morbidity and AIDs-related mortality
among these women. This potential benefit is likely to
decrease with the increase in the availability and use of ARV,
which would imply that most of the HIV-infected women
would be able to manage their disease, spend a long
productive life and reduce AIDs-related mortality.
The present analysis used data on HIV acquisition risk
with hormonal contraception from three prospective
observational studies [1,7–9], which have many strengths
but also suffer from various methodological issues [2–5].
Furthermore, while the HIV acquisition risks (observed
and adjusted) with OC and DMPA were statistically
significant for sex workers [9], the HIV acquisition riskwith OC was statistically significant neither for family
planning users nor for discordant couples [1,7,8]. Neither
were the observed HIV acquisition risks with injectable
contraceptives. The hazard ratio measuring the HIV
acquisition risk became significant marginally for discor-
dant couples with p values of .04 and .05 only after
statistical adjustments [1]. This hazard ratio for family
planning users was not significant after adjustments were
made through Cox proportional hazard model [7], but it
became significant marginally with p value of .04 only
after adjusting through marginal structural model analysis
[8]. These observations suggest that there may be a
variable that negatively confounded the relationship
between HIV acquisition risk and injectable use. None of
these studies, however, identified this confounder that
raised the magnitude of the hazard ratio with injectable and
changed its significance after adjustment. It is possible that
a higher proportion of those women who believed
themselves to be at a high HIV acquisition risk were
already using condom and using it more effectively than
others. Perhaps, this issue can be addressed by estimating
HIV acquisition risks with hormonal and nonhormonal
methods separately for users and nonusers of condom or
for those with protected and unprotected sex. Furthermore,
the absence of statistically significant relationship between
OC use and HIV acquisition among family planning users
and discordant couples may imply that, in addition to the
small number of OC users, either the exposure to OC use
was not collected adequately or estrogen provided some
protection against HIV acquisition.
The issue — whether or not the use of hormonal
contraception actually elevates HIV acquisition risk — is
unlikely to be resolved by behavioral studies alone. We need
to establish biological mechanisms involved with the use of a
specific hormone, its dosage and the route of administration.
While a randomized trial has been suggested [4] to
provide a definite answer, such a trial may not be ethical
and is unlikely to be feasible [1,7]. In order to be
enrolled in such a trial, women would have to be equally
interested in reducing their risk of pregnancy as well as
their risk of HIV acquisition. Offering choice of
appropriate method to reduce the likelihood of an
unwanted pregnancy is one of the basic principles
imbedded in the plan of action [15] emerging from the
1994 International Conference on Population and Devel-
opment. Moreover, the selection of a method depends
upon personal reproductive needs (whether and when to
have the next child: now, later or never), characteristics of
methods, preferences and experiences, and availability and
quality of services. It may be unethical to assign women
even with the same reproductive needs to a specific
method irrespective of their preferences and experiences.
The study would not be feasible because of high rates of
switching among methods, especially if the method
initially assigned does not match the preferences of the
client. Moreover, the effect of bias due to the differences
652 A.K. Jain / Contraception 86 (2012) 645–652in protective behaviors among women who may believe
themselves to be at a high risk of HIV acquisition may be
difficult to eliminate completely.
Such a randomized trial, perhaps, may not even be
needed in view of the analysis presented in this paper,
which assumes that the use of hormonal contraception
actually elevates the risk of HIV acquisition. The results of
any such simulation are likely to be context-specific, and it
would be important to repeat it for other countries with
different context. However, the basic conclusion is unlikely
to change because the present analysis included three
countries with very different contexts. South Africa has one
of the lowest fertility and maternal mortality but high HIV
prevalence. As shown by the results for Kenya and
Zimbabwe, the costs-to-benefit ratio for countries with
higher fertility, higher maternal mortality and lower HIV
prevalence than South Africa would be even higher that
those observed in this study.5. Conclusions
Individual DMPA users may be advised to shift to
sterilization, IUD or implant provided that these methods
match their reproductive needs and circumstance, but not to
OC, no method or even condom alone. At the macro level,
the decision to withdraw DMPA from family planning
programs is not warranted.Acknowledgments
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